Medical device company DeepSight Technology has unveiled its new ultrasound-guided needle technology, NeedleVue.

The new solution has been designed to provide safety in the directed interventional tool guidance field.

NeedleVue combines advanced sensor technology with most interventional devices, enabling real-time verification of placement and lowering procedural guesswork.

Conventional technologies frequently pose difficulties, such as laborious calibration procedures, reduced sensitivity and the requirement for precise angles of incidence.

NeedleVue improves performance with its omnidirectional capability at any plausible ultrasound depth, enhancing functionality in a ‘plug-and-play’ solution.

The plug-and-play system helps eliminate the requirement for complicated setups or broader training.

DeepSight Technology CEO Nader Sadrzadeh said: “NeedleVue not only signifies a monumental leap in the evolution of interventional tool guidance but also substantiates our steadfast commitment to ensuring procedural success, benefiting patients, clinicians and healthcare providers alike.

“In a reality where procedural confidence is paramount, our solution stands out as a beacon of precision and reliability, effortlessly aligning with the multifaceted demands of modern healthcare.”

The company will showcase the NeedleVue solution at the Radiological Society of North America (RSNA), which will be held between 26 and 30 November.

The NeedleVue solution is not currently available for sale or use. It has not received approval from the Food and Drug Administration or any other regulatory authority.

Established in 2019, DeepSight is focused on the development of advanced medical ultrasound technologies.